An observational study in COVID-19 and Diabete Mellitus, sponsored by The University of Texas Health Science Center at San Antonio. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by The University of Texas Health Science Center at San Antonio · Observational
Hospitalized patients with severe COVID-19 have an increased incidence of insulin resistance, impaired beta cell function, glucose intolerance (prediabetes), and overt type 2 diabetes (T2D) compared to non-hospitalized patients with COVID-19 and COVID-19 negative individuals on long-term follow up.
The purpose of this research study is to understand the long-term effects of COVID-19 infection on individuals without any prior history of diabetes. This study will look at several measures of diabetes, such as glycemic control (blood glucose/sugar levels), function of beta cells (cells that make insulin to control sugar), insulin secretion and insulin sensitivity (fasting insulin levels).
The following participants will be enrolled: 1) have had COVID-19 infection and were hospitalized and recovered, or 2) have had mild COVID-19 infection and were seen at outpatient clinics or ER and were not required to be hospitalized, or 3) have not had COVID-19 infection but were seen in outpatient clinics or ER during the same time period.
The researchers hope to learn the long-term effects of COVID-19 infection in hospitalized patients. Specifically, they will be focusing on the subsequent development of diabetes and associated metabolic disturbances, such as impaired insulin secretion and insulin resistance. A relationship between COVID-19 and diabetes needs to be investigated.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 23 is below the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →The University of Texas Health Science Center at San Antonio is the lead sponsor of 435 studies on the registry; 88 are open to participants now.
Of its 62 completed or terminated interventional studies of FDA-regulated products, 31 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Three groups from background (general) population including Mexican ancestry will be studied, who have no history of diabetes or treatment with diabetes drugs prior to COVID-19 infection.
Exclusion Criteria:
Hospitalized in ICU with COVID-19 (PCR positive) and recovered
Other: Measure of physiologic parameters
COVID-19 positive (by PCR) who recovered from mild COVID-19 and were seen in outpatient clinics or ER with symptoms that did not justify hospitalization.
Other: Measure of physiologic parameters
COVID-19 negative (by PCR) and seen in outpatient clinics or ER during same time period as Groups I and II.
Other: Measure of physiologic parameters
Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
Measure of glycosylated glucose percentage (HbA1c)
Change in HbA1c, and indication of glucose levels over a 3 month period
Time frame: Baseline to 24 months
Measure of free plasma glucose (FPG)
Change in FPG
Time frame: Baseline to 24 months
Body Weight
Change in body weight over the study period
Time frame: Baseline to 24 months
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center at San Antonio